Takeda Oncology
Tammie Yeh is a seasoned professional in the field of oncology and translational medicine, currently serving as Senior Director of Precision and Translational Medicine at Takeda Oncology. Tammie has held several key positions at Takeda, including Director roles in Precision and Translational Medicine as well as Clinical Biomarkers Innovation and Development for Hematology/Oncology. Prior experience includes serving as Associate Director of Oncology Translational Medicine at AstraZeneca and leading the Oncology Biomarkers team at Merck, along with a role as Senior Research Scientist at Array BioPharma. Tammie Yeh earned a PhD in Cancer Biology from Stanford University School of Medicine and a BA in Molecular and Cellular Biology from the University of California, Berkeley.
Takeda Oncology
20 followers
In 2008, Takeda Pharmaceutical Company Limited acquired Millennium Pharmaceuticals and the resulting company became exclusively focused on oncology. In 2014, Takeda Oncology was created to become the global headquarters for Takeda’s oncology specialty business unit, in Cambridge, Massachusetts, on the former Millennium Pharmaceuticals site. AtTakeda Oncology they endeavor to deliver novel medicines to patients with cancer worldwide through our commitment to science, breakthrough innovation and passion for improving the lives of patients. This singular focus drives our aspirations to discover, develop and deliver breakthrough oncology therapies. By concentrating the power of leading scientific minds and the vast resources of a global pharmaceutical company, they are finding innovative ways to improve the treatment of cancer.They've built a portfolio of paradigm-changing therapies and a leading oncology pipeline. Though They've made great strides in our fight against cancer, they are determined to do more — to work harder and to reach higher. They continue to seek our aspirations with the same passion, agility and entrepreneurial spirit that has sustained our patient-centric culture and has made us the leaders in oncology that they are today.